Theralase Technologies Inc. V.TLT

Best in class 2and 3 year data

[enriquesuave]

so far we beat all competitors on 2 and 3 year data and by far.  J&J tar 200 is down to 4.7% at 3 years and we are aiming for 21.4% as per Kaplan Meyer projections so far..  This shows how all other treatments show rapidly declining CR rates once they stop treating.  We also beat 2 years data of recently approved combination treatment Anktiva/ BCG.  24%% vs 25.6% for us based on Kaplan Meyer projection.  Can the FDA give us AA or even full approval right away?

[enriquesuave]

https://media.stockhouse.com/media/companies/v-tlt/eqp/Theralase-Corporate-Presentation-08122024.pdf#EQP_PRESENTATION_20240906  

[Eoganacht]

That's right! We are headed for an absolute 21.5 %  CR rate at 3 years! (35.6% of the 60.3% CR at any time patients) More than one fifth of all BCG unresponsive NMIBC patients will be complwtely cured after only 1 or 2 Ruvidar PDT treatments. It's hard to see how this will not be the first treatment urological oncologists will try if they have the best interests of their patients

[TimboBaggins]

Does anyone on this board have any experience or knowledge in the manufacturing of electrical devices? I'm wondering how Theralase will plan to produce more systems when/if they are granted BTD and how long it might take to ramp up production (hopefully non-Chinese) An open North American market doesn't mean much if there are only 15 units available even though each unit could probably do

[Lesalpes29]

Lol Mr Limbo! 

[DeathXray33]

I'm buying more today.

[TommyNickels]

Not a bad idea. Come Tuesday, we are live to a PR saying that pre-BTD was successful. We don't know exactly when it was submitted but the timeframe, from Roger, is "two to three weeks". At this point, what further roadblocks could the FDA put up? My guess for the next PR is Wednesday, October 23. "BTD has been filed. We Expect a response within 60 days. Based on the data, the

[wildbird1]

Thanks Enriquesuave, good post. 1) You are correct, TLT 21.4% at 3 years is huge compared to J&J Tar-200(4.7%). 2) In this link... .Study Details | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Gurin Who Are Ineligible for or Elected Not to

[DeathXray33]

MRK stock is down over 14% in just 3 months. Maybe something is up?

[CancerSlayer]

Yep...the K-M projection for 2-3 year data surpasses Keytruda's 1 year results!  The results will certainly speak for themselves.   A BTD & a load of education/salesmanship need to happen before any shareholder-friendly deal imo.   I'm not sure Big Pharma has a clue about the true potential of our tech as they've been so heavily buried/weighted in favor of chemo

[Pandora]

Anybody here lucky enough to have been in C.DRUG this past week? Certainly not me!

[DeathXray33]

Maybe Johnson would be interested in us. --------------------------------------------------- "Our vision: The elimination of cancer At Johnson & Johnson, we are driven by our bold vision to eliminate cancer. Together, we work diligently to get in front of cancer and will never settle until the disease is behind everyone."

[Alamir1111]

New video out on sh with Rdw